Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices

NCT05626777 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Asthma

Interventions

DRUG: Pre-filled syringe, mepolizumab 100 mg/month
DRUG: Auto-injector pen, mepolizumab 100 mg/month

Sponsor

Hospices Civils de Lyon

Collaborators

[object Object]